We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

53 hedge funds and large institutions have $143M invested in NKGen Biotech, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

16% more capital invested

Capital invested by funds: $123M → $143M (+$19.2M)

10% more funds holding

Funds holding: 48 → 53 (+5)

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

Holders
53
Holders Change
+5
Holders Change %
+10.42%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MF
Magnetar Financial
Illinois
+$8.97M
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$8.78M
3
Marshall Wace
Marshall Wace
United Kingdom
+$5.23M
4
MP
Mangrove Partners
Connecticut
+$1.79M
5
GF
Gabelli Funds
New York
+$1.76M

Top Sellers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
-$5.1M
2
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$1.59M
3
CL
CSS LLC
Illinois
-$1.29M
4
FBCM
Fort Baker Capital Management
California
-$981K
5
UOC
UBS O'Connor
Illinois
-$318K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$13.2M – – –
HCM
2
Highbridge Capital Management
New York
$11.9M +$982K +100,609 +9%
MF
3
Magnetar Financial
Illinois
$9.75M +$8.97M +919,400 +1,141%
BNP Paribas Financial Markets
4
BNP Paribas Financial Markets
France
$7.33M +$8.78M +900,000 New
RCM
5
Radcliffe Capital Management
Pennsylvania
$5.88M – – –
PC
6
Periscope Capital
Ontario, Canada
$5.84M -$3.9K -400 -0.1%
Marshall Wace
7
Marshall Wace
United Kingdom
$5.75M +$5.23M +535,635 +990%
CSS
8
Cubist Systematic Strategies
Connecticut
$4.95M +$70.2K +7,196 +1%
FTCM
9
Fir Tree Capital Management
New York
$4.88M – – –
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
10
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$4.88M – – –
6CM
11
683 Capital Management
New York
$4.69M -$184K -18,810 -4%
KL
12
KIM LLC
Kansas
$4.49M – – –
SCM
13
Saba Capital Management
New York
$4.05M – – –
Balyasny Asset Management
14
Balyasny Asset Management
Illinois
$3.9M – – –
PSAMP
15
P. Schoenfeld Asset Management (PSAM)
New York
$3.9M – – –
Goldman Sachs
16
Goldman Sachs
New York
$3.56M – – –
TCA
17
Taconic Capital Advisors
New York
$3.41M – – –
UOC
18
UBS O'Connor
Illinois
$3.12M -$318K -32,585 -9%
PAMP
19
Polar Asset Management Partners
Ontario, Canada
$2.92M – – –
GF
20
Gabelli Funds
New York
$2.73M +$1.76M +180,000 +179%
CF
21
Cantor Fitzgerald
New York
$2.49M – – –
D.E. Shaw & Co
22
D.E. Shaw & Co
New York
$2.46M – – –
SCM
23
Shaolin Capital Management
Florida
$2.38M -$92.7K -9,498 -4%
Millennium Management
24
Millennium Management
New York
$2.38M – – –
FBCM
25
Fort Baker Capital Management
California
$1.96M -$981K -100,557 -33%
1
2 3

NKGN Hedge Fund Activity: Q3 2022 in Review

53 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q3 2022, worth a combined $143M — up 16% from $123M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new NKGN positions and 3 closed out — a net gain of 6 holders — while 8 added to existing stakes and 8 trimmed.

The largest buyer was Magnetar Financial, adding an estimated $8.97M. The largest seller was Kepos Capital, exiting entirely with an estimated $5.1M sold.

  • 53 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q3 2022, up from 48 in Q2 2022.
  • Funds reported $143M of NKGen Biotech, Inc. Common Stock stock for Q3 2022, up 16% quarter-over-quarter.
  • 9 funds opened new NKGen Biotech, Inc. Common Stock positions in Q3 2022 and 3 closed out, a net change of +6 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q3 2022 was Magnetar Financial, an estimated $8.97M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q3 2022 was Kepos Capital, an estimated $5.1M sold.

Based on aggregated 13F filings for Q3 2022.